Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PGK1 | P00558 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25789664 | 0.83 | KDM4E (0.32) | ALDH1A1KDM4EGAASMN1; SMN2MAPT | |
| SCHEMBL30718899 | 0.82 | DDR1 (0.33) | ALDH1A1KDM4EGAASMN1; SMN2DDR1 | |
| SCHEMBL23141780 | 0.82 | DDR1 (0.33) | ALDH1A1KDM4EGAASMN1; SMN2DDR1 | |
| SCHEMBL19325391 | 0.81 | CYP3A4 (0.37) | CYP3A4TSHRRECQLALDH1A1GAA | |
| SCHEMBL502070 | 0.80 | ERN1 (0.33) | CYP3A4ALDH1A1KDM4ESMN1; SMN2MAPT | |
| SCHEMBL31139452 | 0.80 | ERN1 (0.33) | CYP3A4ALDH1A1KDM4ESMN1; SMN2MAPT | |
| SCHEMBL17119689 | 0.80 | CYP2C19 (0.37) | TSHRRECQLALDH1A1KDM4EGAA | |
| SCHEMBL23884988 | 0.80 | ALDH1A1 (0.41) | ALDH1A1KDM4ESMN1; SMN2LMNAMAPT | |
| SCHEMBL20330630 | 0.79 | DDR1 (0.33) | DDR1 | |
| SCHEMBL23884981 | 0.78 | ERN1 (0.39) | CYP3A4KDM4EERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12521395-B2 | Gem-disubstituted heterocyclic compounds and their use as IDH inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2026-01-13 | — | — | US | disclosed |
| US-12351576-B2 | FGFR inhibitor, preparation method therefor and application thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2025-07-08 | — | — | US | disclosed |
| EP-4055015-B1 | GEM-DISUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IDH INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2025-04-02 | — | — | EP | disclosed |
| EP-4476218-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF RIPRETINIB | Assia Chemical Industries Ltd. (IL) | 2024-12-18 | — | — | EP | disclosed |
| US-12018023-B2 | Heterocondensed pyridones compounds and their use as IDH inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2024-06-25 | — | — | US | disclosed |
| US-12018023-B2 | Heterocondensed pyridones compounds and their use as IDH inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2024-06-25 | — | — | US | disclosed |
| US-12018023-B2 | Heterocondensed pyridones compounds and their use as IDH inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2024-06-25 | — | — | US | disclosed |
| CN-112469719-B | Heterocondensed pyridone compounds and their use as IDH inhibitors | 内尔维亚诺医疗科学公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-113004278-B | Bicyclic heterocycles as FGFR inhibitors | 因赛特控股公司 | 2023-07-21 | — | — | CN | disclosed |
| WO-2023122322-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF RIPRETINIB | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2023-06-29 | — | — | WO | disclosed |
| US-20090312321-A1 | COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS | IRM LLC (BM) | 2009-12-17 | — | — | US | disclosed |
| US-20090312321-A1 | COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS | IRM LLC (BM) | 2009-12-17 | — | — | US | disclosed |
| CN-101553232-A | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS LLC (US) | 2009-10-07 | — | — | CN | disclosed |
| CN-101460175-A | Compositions and methods for FGF receptor kinase inhibitors | IRM LLC (BM) | 2009-06-17 | — | — | CN | disclosed |
| EP-2063897-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC. (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-2018167-A2 | COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS | IRM LLC (BM) | 2009-01-28 | — | — | EP | disclosed |
| US-20080114006-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| WO-2008034008-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2007136465-A2 | COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS | IRM LLC (BM) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007136465-A2 | COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS | IRM LLC (BM) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018023-B2 | Heterocondensed pyridones compounds and their use as IDH inhibitors | IDH1, IDH2, IDH3A | CYP3A4 916/4885TSHR 4561/4885RECQL 80/4885 |
| US-20090312321-A1 | COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS | PTK2B, SGK2, FRK | CYP3A4 4486/4885TSHR 1063/4885RECQL 3588/4885 |
| US-12351576-B2 | FGFR inhibitor, preparation method therefor and application thereof | FGFR1, FGFR3, FGFR4 | CYP3A4 4428/4885TSHR 2496/4885RECQL 3493/4885 |
| US-20080114006-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | BRAF, PRKDC, RAF1 | CYP3A4 3505/4885TSHR 283/4885RECQL 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.